SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, announced it has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx) IL-6 Severity Triage Test. RALI-Dx is the first interleukin-6 (IL-6) diagnostic test approved in Canada, and its turnaround time of less than an hour is developed to fill an important and unmet public health need.
